In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains

Aktas, Gülseren; Derbentli, Sengul

doi:10.1016/j.jgar.2017.05.022

In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains

Atıf İçin Kopyala

Aktas G., Derbentli S.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, cilt.10, ss.223-227, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 10
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.jgar.2017.05.022
Dergi Adı: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.223-227
İstanbul Üniversitesi Adresli: Evet

Özet

Objectives: Although new antimicrobial agents designed to treat infections with limited therapeutic options have been introduced in the past few years, resistant Gram positive cocci have continued to emerge and spread. Daptomycin is a cyclic lipopeptide antibiotic that has rapid bactericidal activity against broad spectrum of Gram positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). Antibiotics are sometimes used in combination in an attempt to prevent or delay the in vivo emergence of drug-resistant subpopulations of pathogenic organisms. The aim of the study was to evaluate in vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin, and fusidic acid against MRSA strains.